All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
2 型糖尿病患者使用鈉葡萄糖共同運輸蛋白 2 抑製劑、葡萄糖樣胰高血糖素受體激動劑以及聯合治療的全因死亡率和心血管結果。
Diabetes Obes Metab 2023-09-05
The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.
在接受胰高血糖素樣肽-1受體激動劑治療的日本2型糖尿病患者中，聯合使用鈉葡萄糖共同運輸蛋白2抑製劑改善了腎臟結果。
Cardiovasc Endocrinol Metab 2023-10-04
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
糖尿病患者合併使用SGLT2抑制劑、GLP-1受體激動劑和非類固醇MRA，與傳統治療相比，在預估終身心血管、腎臟和死亡益處方面的研究。
Circulation 2024-04-03
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication.
糖尿病患者合併使用鈉葡萄糖共同轉運蛋白抑制劑和 GLP-1 受體激動劑的腎保護效應：根據先前用藥情況。
Diab Vasc Dis Res 2023-12-18
Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies.
二型糖尿病患者合併使用鈉葡萄糖轉運蛋白2抑制劑和葡萄糖樣肽-1受體激動劑的效果和安全性：觀察性研究的系統性回顧和荟萃分析。
Cardiovasc Diabetol 2024-03-21
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.
SGLT2抑制劑和GLP-1受體激動劑聯合應用對2型糖尿病患者eGFR下降的影響：RECAP研究的事後分析。
Front Pharmacol 2024-04-25
Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
葡萄糖樣肽-1 受體激動劑和鈉-葡萄糖共同運輸蛋白-2 抑制劑聯合治療對心血管和嚴重腎臟事件發生率的影響：基於人群的世代研究。
BMJ 2024-04-25
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
在患有第2型糖尿病和慢性腎臟病的患者中，先前藥物治療對聯合使用鈉葡萄糖共同轉運蛋白2抑製劑和葡萄糖樣肽-1受體激動劑治療的腎臟和心血管結果的影響。
Diabetes Obes Metab 2024-05-20